Fulcrum Therapeutics, Inc. (FULC) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1243570,
    "name": "Fulcrum Therapeutics, Inc.",
    "stock_name": "Fulcrum Therapeutics, Inc.",
    "full_name": "Fulcrum Therapeutics, Inc.",
    "name_url": "stocks-analysis/fulcrum-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "8.76",
    "chg": -0.19,
    "chgp": "-2.12%",
    "dir": -1,
    "prev_price": "8.95",
    "mcapval": "393.25",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US3596161097",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.64 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/fulcrum-therapeutics-inc-1243570-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Fulcrum Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-fulcrum-therapeutics-inc-technically-bullish-or-bearish-3547671",
        "imagepath": "",
        "date": "2025-09-20 20:00:27",
        "description": "As of 30 July 2025, the technical trend for Fulcrum Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish daily moving average and a bullish monthly Bollinger Band. However, the weekly MACD and KST indicators are mildly bearish, indicating some caution. \n\nIn terms of performance, the company has shown strong returns, outperforming the S&P 500 significantly with a 1-year return of 119.19% compared to the S&P's 17.14%, and a year-to-date return of 60.43% against the S&P's 12.22%...."
      },
      {
        "title": "Is Fulcrum Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-fulcrum-therapeutics-inc-overvalued-or-undervalued-3543974",
        "imagepath": "",
        "date": "2025-09-20 18:34:09",
        "description": "As of 29 July 2025, the valuation grade for Fulcrum Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears overvalued, particularly when considering its P/E ratio of 252, which is substantially higher than typical industry benchmarks, and a PEG ratio of 2.48, suggesting that the stock is priced high relative to its expected growth. Additionally, the negative EV to EBIT and EV to EBITDA ratios of -16.05 and -18.80 further highlight the company's struggles in generating earnings relative to its enterprise value.\n\nIn comparison to its peers, KalVista Pharmaceuticals, Inc. has a P/E of -4.3845 and MacroGenics, Inc. has a P/E of -3.0562, both reflecting a more favorable valuation relative to Fulcrum. Despite a strong year-to-date return of 60.43% compared to the S&P 500's 12.22%, the long-term performance shows a decline of 14..."
      }
    ],
    "total": 7,
    "sid": "1243570",
    "stock_news_url": "https://www.marketsmojo.com/news/fulcrum-therapeutics-inc-1243570"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Fulcrum Therapeutics, Inc. technically bullish or bearish?

2025-09-20 20:00:27

As of 30 July 2025, the technical trend for Fulcrum Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish daily moving average and a bullish monthly Bollinger Band. However, the weekly MACD and KST indicators are mildly bearish, indicating some caution. In terms of performance, the company has shown strong returns, outperforming the S&P 500 significantly with a 1-year return of 119.19% compared to the S&P's 17.14%, and a year-to-date return of 60.43% against the S&P's 12.22%....

Is Fulcrum Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:34:09

As of 29 July 2025, the valuation grade for Fulcrum Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears overvalued, particularly when considering its P/E ratio of 252, which is substantially higher than typical industry benchmarks, and a PEG ratio of 2.48, suggesting that the stock is priced high relative to its expected growth. Additionally, the negative EV to EBIT and EV to EBITDA ratios of -16.05 and -18.80 further highlight the company's struggles in generating earnings relative to its enterprise value. In comparison to its peers, KalVista Pharmaceuticals, Inc. has a P/E of -4.3845 and MacroGenics, Inc. has a P/E of -3.0562, both reflecting a more favorable valuation relative to Fulcrum. Despite a strong year-to-date return of 60.43% compared to the S&P 500's 12.22%, the long-term performance shows a decline of 14...

View All News